银发经济或成下一个风口(共8份)
银发经济或成下一个风口
-
艾媒咨询|2021全球与中国医药电商市场与发展趋势研究报告
本报告研究涉及企业/品牌/案例:阿里健康,美团,京东健康,叮当快药,1药网,Walgreens,百度健康,药材买卖网,中药材天地网,找药网,九州通,药易购,珍诚医药在线,CVS
在政策利好、互联网技术等多重因素推动下,中国医药电商行业规模持续快速发展,2020年中国医药电商市场交易规模达到1956亿元。当前,中药电商商业模式主要为B2B、B2C、O2O与DTP四种类型,其中,2020年,医药电商B2C模式占比近6%,市场规模为116亿元;医药电商B2C模式占比近84%,市场规模为1640亿元,成为当前的主流。此外,近几年兴起的O2O模式,主要通过“引流-转化-消费-反馈”等实现盈利,而DTP药房模式下,患者在医院开取处方后,药房根据处方以患者或家属指定的时间和地点送药上门,被称为高值新特药直送平台。
Driven by favorable policies, Internet technology and other factors, the scale of China's pharmaceutical e-commerce industry continues to develop rapidly, with the transaction scale of China's pharmaceutical e-commerce market reaching 1956 billion yuan in 2020. At present, the business models of traditional Chinese medicine e-commerce are mainly B2B, B2C, o2o and DTP. In 2020, the B2C model of pharmaceutical e-commerce accounts for nearly 6% and the market scale is 11.6 billion yuan; the B2C model of pharmaceutical e-commerce accounts for nearly 84% and the market scale is 164 billion yuan, which has become the current mainstream. In addition, the o2o mode, which has sprung up in recent years, mainly achieves profits through "drainage transformation consumption feedback". In the DTP pharmacy mode, after patients get prescriptions in the hospital, the pharmacy delivers drugs to the door at the time and place designated by the patients or their families according to the prescriptions, which is known as the high value new special drugs direct delivery platform. -
艾媒报告 |2019全球与中国医药电商市场与发展趋势研究报告
本报告研究涉及企业/品牌/案例:天猫医馆,七乐康,京卫大药房,阿里健康大药房,京东大药房,健客, 1药网,360好药,八百方,818医药网,CVS,Walgreens ,RiteAid ,开心人网上药店,药房网,药材买卖网,珍材网,中药材天地网,商康网,科欣医药,医药在线,我的医药网,药品交易网,药品终端网,药师帮,海王晨星,快方送药,药给力,搜药送,药急送,U医U药,叮当送药,健客网上药店,康爱多掌上药店,问药,好药师,111集团,中宏保险,医联,腾讯,仁和药业,浙江扁鹊,漱玉平民,华人健康,一树药业,德生堂
2019中国医药电商主要形成了B2C、B2B、O2O三种模式,B2C模式体量稳定在6%左右,规模呈增长趋势,预计2019年的市场交易额将达到554.6亿元;B2B模式下,西药类产品的需求比例较高,达87.1%,中药材、传统药品和第三方交易等都形成了专属B2B平台;而近几年兴起的O2O模式,主要通过“引流-转化-消费-反馈”等实现盈利,但区域覆盖度和消费者的信任度需要提高。iiMedia Research(艾媒咨询)大数据监测显示,目前1药网、健客网上药店、康爱多掌上药店的的综合实力排行较强。
2019 China's pharmaceutical e-commerce mainly formed three modes of B2C, B2B and O2O. The volume of B2C model is stable at around 6%, and the scale is increasing. It is expected that the market transaction volume in 2019 will reach 55.46 billion yuan; in B2B mode, western medicine The demand ratio of products is relatively high, reaching 87.1%. Chinese herbal medicines, traditional medicines and third-party transactions have formed a proprietary B2B platform. In recent years, the O2O model has emerged mainly through “drainage-conversion-consumption-feedback”. Achieve profitability, but regional coverage and consumer trust need to be improved. iiMedia Research (Ai Media Consulting) big data monitoring shows that the current comprehensive strength of 1 drug network, Jianke online pharmacy, Kang Aiduo pharmacy is strong. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
- 1
- 2
- 3
- 4
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告